** Shares of Sinopharm Group 1099.HK rise 4.1% to HK$18.14, the biggest intraday pct gain since October 7
** Stock hits the highest point since April 23, snapping three straight session of losses, and is top pct gainer in the Hang Seng Index .HSI, which climbs 0.2%
** The Chinese pharmaceutical, healthcare products and medical devices distributor said its first-quarter net profit up 2.6% y/y at 1.46 billion yuan ($200.11 million) while revenue down 3.8% y/y at 141.7 billion yuan
** Citi keeps "buy" rating given Sinopharm's earnings growth potential from expectations of industry consolidation down the road, likely market share gain due to network expansion and less concern on finance costs
** Hang Seng Commerce & Industry Index .HSNC slips 0.2%, healthcare index .HSCIH falls 1.5%** Stock down 14.9% YTD
($1 = 7.2961 Chinese yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.